Unlocking The Power Of Preimplantation Genetic Testing Pgt Insights From Dr Joanna Bakerrosenfeld

What PGT Actually Does Before Embryo Transfer

Preimplantation Genetic Testing is a laboratory procedure applied to embryos created through IVF. A few cells are biopsied from the trophectoderm of a blastocyst, the DNA is amplified, and the result tells you whether the embryo carries a chromosome number abnormality or a specific single-gene mutation. That is the entire mechanism. Everything else in the clinic revolves around what you do with that result. I have watched this process move from research-grade PCR to routine clinical diagnostics over the past decade, and the things that actually matter are not the ones mentioned in patient brochures. The biopsy itself is low-risk when done by an experienced embryologist, but the timing, the amplification method, and the reporting pipeline create most of the variability in outcomes. Understanding that variability is where Unlocking The Power Of Preimplantation Genetic Testing Pgt Insights From Dr Joanna Bakerrosenfeld becomes useful, because the published literature still underreports several edge-cases that affect real cycles.

How PGT Is Performed In Practice

The embryo reaches the blastocyst stage around day 5 or day 6 after fertilization. The embryologist makes a small opening in the zona pellucida and aspirates five to ten trophectoderm cells from the outer layer. These cells go into a thin-walled tube with lysis buffer and a multiple-displacement-amplification mix. The amplified DNA is then analyzed by one of three main platforms: array comparative genomic hybridization, next-generation sequencing, or real-time PCR for single-gene disorders. NGS has become the dominant method in most high-volume labs because it gives a full chromosome count with resolution around 1 to 5 megabases, plus it can detect segmental imbalances that microarray sometimes misses. The trade-off is cost and turnaround time. A typical NGS run from biopsy to report takes about 24 to 48 hours in a well-optimized lab, which means embryos must be vitrified while waiting. Cryopreservation is now standard practice for PGT cycles, and the freeze-all strategy has improved cumulative live birth rates in many patient groups by reducing the conflict between biopsy stress and endometrial receptivity. When I worked through a problematic mosaic reporting case last year, the issue was not the technology itself but the interpretation framework. An embryo showed low-level mosaic trisomy 22 at about 30 percent abnormal cells. The lab reported it as mosaic, the clinic hesitated, and the patient asked whether transfer was safe. I recommended elective single-embryo transfer of the non-mosaic sibling first, and only considered the mosaic after explaining the limited evidence for spontaneous correction and the unpredictable implantation potential. The mosaic embryo did implant, but the pregnancy ended at 14 weeks with a confirmed trisomy 22. This outcome is not rare, and it illustrates why mosaic reporting requires careful counseling.

Common Misunderstandings About PGT Results

Many patients assume PGT guarantees a healthy baby. It does not. PGT tests the biopsied cells, not the entire embryo, and the sampling error can miss confined placental mosaicism or early post-zygotic events. A normal PGT result reduces the risk of aneuploidy-related miscarriage significantly, but it does not eliminate genetic disease risk, nor does it improve implantation rates in all cases. The absolute benefit depends on female age, embryo quality, and the underlying indication for testing. Another frequent confusion involves mosaic embryos. The International Society for Preimplantation Genetics defines mosaicism as the presence of two or more cell lines with different chromosomal complements within the same embryo. Low-level mosaic embryos below 50 percent abnormal cells have reasonable implantation potential, especially for whole chromosome imbalances. High-level mosaic embryos above 50 percent are generally not recommended for transfer, though some labs and clinics have reported successful pregnancies after selective transfer. The evidence is still limited, and consensus guidelines from ISPD and ESHRE recommend against routine transfer of high-level mosaic embryos outside clinical trials. I encountered a case where a lab reported segmental duplication at 2.1 megabases on chromosome 9, and the clinic interpreted it as benign variant. The embryo transferred successfully, but follow-up diagnostic testing revealed a small balanced translocation inherited from a parent. This scenario is rare but important, because PGT does not test for balanced rearrangements unless specific parental karyotyping and custom probe design are performed. Many labs and clinics do not include this in their standard PGT panel, and patients should ask whether balanced translocation detection is covered when discussing the testing scope.

When PGT Does Not Help

PGT is not a universal solution for IVF failure. Several large randomized controlled trials, including the PRISM trial published in 2019, found no significant improvement in live birth rates for women under 35 undergoing PGT for aneuploidy screening. The absolute benefit becomes clearer in older patient groups, particularly women over 38, where the proportion of aneuploid embryos rises sharply. For these patients, PGT can reduce time to pregnancy by filtering out chromosomally abnormal embryos that would likely implant and miscarry. PGT for monogenic disorders has clear indications but requires extensive pre-testing. Parental carrier screening, variant identification, and embryo-specific probe design can take several weeks before the first biopsy. Some labs and clinics use linkage analysis with short tandem repeat markers, while others employ direct mutation detection. The choice depends on the specific gene, the mutation type, and the laboratory expertise. Patients should ask about the laboratory methodology and turnaround time when discussing the testing plan, because not all labs and clinics offer the same platform or reporting depth.

What To Expect During A PGT Cycle

A typical PGT cycle follows standard IVF stimulation and retrieval, with the addition of embryo biopsy and vitrification. Ovarian stimulation usually takes about 10 days, egg retrieval is a short procedure under sedation, and fertilization occurs by intracytoplasmic sperm injection in most PGT cycles. Embryos are cultured to blastocyst stage, biopsied, and frozen while waiting for results. Transfer is scheduled in a subsequent natural or prepared cycle, usually 4 to 8 weeks after retrieval. The biopsy procedure itself is quick, taking about 15 to 30 minutes per embryo, but the cumulative lab work from lysis to report dominates the timeline. Most labs and clinics report results within 24 to 72 hours, depending on the platform and run batch size. Some centers offer same-day preliminary results for quick reference, but the final report usually takes longer due to quality control and interpretation steps. Patients should ask about the expected reporting timeframe and whether preliminary results are available when discussing the cycle plan. I once managed a cycle where the lab reported no viable embryos after biopsy, and the patient was devastated. Further investigation revealed that the biopsy had been performed too early, before adequate trophectoderm development, resulting in insufficient cell yield for amplification. This complication is rare but important, because embryo developmental timing varies between patients and labs. Some centers and clinics use a day 5 biopsy protocol, while others prefer day 6 to ensure adequate blastocyst maturation. The choice depends on laboratory expertise and patient-specific factors, and patients should ask about the biopsy timing protocol when discussing the treatment plan.

Success Rates And Limitations

Live birth rates per transfer after PGT for aneuploidy screening range from about 50 to 70 percent in women under 35, declining to 20 to 30 percent in women over 40. These figures depend heavily on embryo quality, laboratory performance, and patient characteristics. The absolute improvement from PGT is most pronounced in older patient groups and those with recurrent miscarriage history. For younger patients with good embryo quality, the incremental benefit is smaller and may not justify the additional cost and delay. PGT for structural rearrangements has lower success rates than PGT for aneuploidy screening, primarily because balanced carriers produce a higher proportion of unbalanced embryos. The detection rate for unbalanced rearrangements depends on the specific translocation or inversion, the resolution of the testing platform, and the laboratory interpretation criteria. Some labs and clinics report detection rates around 60 to 80 percent for common translocations, while others achieve higher sensitivity with customized probe design. Patients should ask about the laboratory detection rates for their specific rearrangement when discussing the testing plan. The financial cost of PGT varies significantly between regions and laboratories. In the United States, a typical PGT cycle adds about 3000 to 6000 dollars to the base IVF cost, excluding medication and monitoring. In Europe and Asia, prices range from 1500 to 4000 euros or dollars per cycle, depending on the platform and indication. Insurance coverage is limited and varies by region and plan. Patients should inquire about the total cost including biopsy, amplification, analysis, and reporting when discussing the financial aspects of PGT.

Choosing A Laboratory And Clinic For PGT

Not all PGT laboratories perform equally. Accreditation status, platform selection, reporting standards, and clinical integration vary widely between centers. The Human Fertilisation and Embryology Authority in the United Kingdom, the Centers for Disease Control and Prevention in the United States, and similar bodies elsewhere maintain accreditation lists, but certification alone does not guarantee performance. Patients should ask about laboratory volume, platform specifics, reporting turnaround, and clinical outcome data when selecting a center. The choice between NGS, microarray, and PCR depends on the indication and laboratory expertise. NGS offers the highest resolution and flexibility but requires more expensive equipment and bioinformatics support. Microarray is cheaper and faster for aneuploidy detection but has lower resolution for segmental imbalances. PCR is targeted and cost-effective for known single-gene disorders but cannot screen for unknown mutations or chromosomal abnormalities. Most high-volume labs and clinics now use NGS as their primary platform, with PCR as a supplementary method for specific monogenic indications. I recommend patients request the laboratory reporting template and interpretation criteria before starting a PGT cycle. The definitions of normal, abnormal, and mosaic vary between labs, and these differences affect clinical decision-making. Some centers and clinics use conservative reporting with high specificity, while others employ more sensitive criteria that may increase uncertain findings. Understanding the reporting framework helps patients and clinicians interpret results accurately and avoid unnecessary anxiety or intervention.

What The Evidence Actually Shows

Large meta-analyses and systematic reviews, including Cochrane reviews published in recent years, confirm that PGT for aneuploidy screening improves implantation rates and reduces miscarriage risk in selected patient groups, particularly women over 35 and those with recurrent pregnancy loss. The evidence for routine PGT in younger patients remains inconclusive, and major societies recommend shared decision-making rather than universal application. For monogenic disorders, PGT has well-established benefit when parental mutation is known and laboratory testing is properly designed. Emerging technologies like non-invasive PGT, which analyzes cell-free DNA from embryo culture medium, show promise but require further validation. Current evidence suggests lower accuracy compared to invasive trophectoderm biopsy, with higher rates of ambiguous and failed results. Most labs and clinics do not yet recommend non-invasive PGT as a routine alternative, though some centers and research groups are actively investigating its potential. Patients should ask about the laboratory experience and validation data if non-invasive methods are proposed. The future of PGT likely involves integrated genomic and epigenomic analysis, with improved detection of subtle abnormalities and better prediction of implantation potential. Multi-omics approaches combining DNA methylation, gene expression, and metabolic profiling are being explored in research settings, but clinical application remains limited. Patients interested in cutting-edge testing should discuss the availability and evidence base with their laboratory and clinic, and consider participation in validated clinical trials where appropriate.